- Disease:Metabolic dysfunction-associated liver disease
- Substances:Ly3437943 SodiumTirzepatide
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Ly3437943 Sodium
Find therapies in clinical trials near you – page 8
- recruiting
- 3 961
- countries
- 28
- conditions
- 2 103
3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today
736 trials match your criteria
Recruiting
Gastrooesophageal cancer
RecruitingRegistered drugNo placebo
Evaluation of Safety and Efficacy of MK-2870 and Paclitaxel in Second-Line Treatment of Advanced/Metastatic Gastroesophageal Adenocarcinoma
Registered drugNo placebo
- Disease:Gastrooesophageal cancer
- Substances:Codeine PhosphatePaclitaxel+6
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Codeine Phosphate
Recruiting
Hyperparathyroidism secondary
RecruitingRegistered drugNo placebo
Phase 3 Evaluation of Etelcalcetide for Secondary Hyperparathyroidism in Pediatric Patients with Chronic Kidney Disease on Hemodialysis
Registered drugNo placebo
- Disease:Hyperparathyroidism secondary
- Substances:Etelcalcetide
Countries:Germany
Germany- Participants:0–17 years
- Substances:Etelcalcetide
Recruiting
Acute kidney injury
RecruitingInvestigational
A study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis
Investigational
- Disease:Acute kidney injury
- Substances:–
Countries:Germany
Germany- Participants:18–64 years · 65+ years
Recruiting
Neuroendocrine carcinoma of the skin
RecruitingRegistered drug
A Study of Cemiplimab Given Before Surgery in Patients with Early Stage Merkel Cell Carcinoma of the Skin
Registered drug
- Disease:Neuroendocrine carcinoma of the skin
- Substances:Cemiplimab
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Cemiplimab
Recruiting
Hodgkin's disease
RecruitingRegistered drugNo placebo
A Study of Pembrolizumab and Radiotherapy for Patients with Early-Stage Favorable Classic Hodgkin Lymphoma
Registered drugNo placebo
- Disease:Hodgkin's disease
- Substances:Pembrolizumab
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
Recruiting
Squamous cell carcinoma of lung+8
RecruitingRegistered drugNo placebo
A study testing BNT326 and BNT327 with drug combination for safety and effectiveness in people with advanced non-small cell lung cancer
Registered drugNo placebo
- Disease:Squamous cell carcinoma of lungNon-small cell lung cancer+7
- Substances:BNT327Carboplatin+3
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:BNT327
Recruiting
Neoplasm malignant+1
RecruitingRegistered drugNo placebo
Study of ECI830, ribociclib, and fulvestrant in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors
Registered drugNo placebo
- Disease:Neoplasm malignantHormone receptor positive HER2 negative breast cancer
- Substances:FulvestrantGoserelin+2
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Fulvestrant
Recruiting
Acute myeloid leukaemia
RecruitingInvestigational
A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.
Investigational
- Disease:Acute myeloid leukaemia
- Substances:BLEXIMENIB
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:BLEXIMENIB
Recruiting
Parkinson's disease
RecruitingInvestigational
A study comparing prasinezumab with placebo for people with early-stage Parkinson's disease
Investigational
- Disease:Parkinson's disease
- Substances:Prasinezumab
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Prasinezumab
Recruiting
Non-small cell lung cancer
RecruitingRegistered drugNo placebo
A Study of Telisotuzumab Adizutecan Compared to Standard Treatment in Adults with Advanced Non-Small Cell Lung Cancer After Previous Treatment
Registered drugNo placebo
- Disease:Non-small cell lung cancer
- Substances:AmivantamabCarboplatin+3
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Amivantamab
Recruiting
B-cell type acute leukaemia
RecruitingRegistered drugNo placebo
Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia
Registered drugNo placebo
- Disease:B-cell type acute leukaemia
- Substances:Blinatumomab
Countries:Germany
Germany- Participants:0–17 years · 18–64 years
- Substances:Blinatumomab